Literature DB >> 2972943

Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue.

S Itagaki1, P L McGeer, H Akiyama.   

Abstract

Cells expressing leucocyte common antigen (LCA) as well as T-cytotoxic-suppressor (T8) and T-helper-inducer (T4) antigens were detected in significant numbers in the hippocampus and temporal cortex of Alzheimer but not normal brain tissue. Leucocytes and reactive microglia strongly expressed LCA, as well as the class II major histocompatibility complex (MCH) glycoprotein HLA-DR, but astrocytes stained negatively. Such staining indicates the immunocompetent status of microglia, as well as their phenotypic linkage to blood borne mesodermal lines. T8 and T4 positive lymphocytes were detected in capillaries and the surrounding matrix in smaller numbers than LCA positive cells. The MHC class I (HLA-A,B,C) antigens were detected on capillaries in both Alzheimer and control tissue. The significance of LCA, T4 and T8 cells in Alzheimer's disease is unknown but may be indicative of a cell mediated immune response in the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972943     DOI: 10.1016/0304-3940(88)90690-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  62 in total

1.  Vimentin immunoreactivity in normal and pathological human brain tissue.

Authors:  T Yamada; T Kawamata; D G Walker; P L McGeer
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Microglial TNF-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration.

Authors:  Yi-Ming Yang; De-Shu Shang; Wei-Dong Zhao; Wen-Gang Fang; Yu-Hua Chen
Journal:  Neurochem Res       Date:  2013-08-29       Impact factor: 3.996

3.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

Review 4.  The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease.

Authors:  Marina A Lynch
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

5.  Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease.

Authors:  H Akiyama; H Tago; S Itagaki; P L McGeer
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 6.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

7.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

Review 8.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 10.  Inflammatory mechanisms in neurodegeneration.

Authors:  Michael R Nichols; Marie-Kim St-Pierre; Ann-Christin Wendeln; Nyasha J Makoni; Lisa K Gouwens; Evan C Garrad; Mona Sohrabi; Jonas J Neher; Marie-Eve Tremblay; Colin K Combs
Journal:  J Neurochem       Date:  2019-03-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.